Treatment for relapse of acute myeloid leukemia after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness and safety of a treatment regimen combining VMAC (venetoclax, liposomal mitoxantrone, cytarabine, and cyclophosphamide) with donor lymphocyte infusion (DLI) for patients who have relapsed acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation. The study includes 30 participants and aims to monitor the occurrence of serious infections, cardiac toxicity, and graft-versus-host disease (GVHD) during treatment. Patients will be evaluated for efficacy through blood tests and bone marrow examinations four weeks after DLI, with follow-up extending for two years to assess long-term outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with AML confirmed by bone marrow morphology and morphological recurrence after allo-HSCT (proportion of bone marrow morphological blast cells ≥5%);
2. Age ≥18 years and ≤65 years old, regardless of gender;
3. Eastern Oncology The evaluation of physical status of the cooperative group (ECOG-PS) is 0-2 points;
4. An informed consent form must be signed before the start of the research procedure, and the patient himself or his immediate family members must sign the informed consent form. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member will sign the informed consent form.

Exclusion Criteria:

Subjects who meet any of the following criteria shall not be enrolled in this study:

* 1\) Secondary transplant patients;
* 2\) Have a history of tumor and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer , basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN) or prostate intraepithelial carcinoma (PIN);
* 3\) Serological reactions of known HIV, active hepatitis B, and active hepatitis C virus positive or syphilis positive;
* 4\) Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring;
* 5\) Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment;
* 6\) Active heart disease, definition One or more of the following:

  1. Long QTc syndrome or QTc interval \>480ms;
  2. Complete left bundle branch block, II or III degree atrioventricular block;
  3. Need for drug treatment or History of severe arrhythmia with clinical symptoms;
  4. New York Heart Association classification ≥ II;
  5. Left ventricular ejection fraction less than 50%;
  6. Myocardial infarction, unstable angina, severe myocardial infarction within 6 months before enrollment History of unstable ventricular arrhythmias or any other arrhythmias requiring treatment, clinically severe pericardial disease, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
* 7\) Transplantation from an unrelated donor;
* 8\) Those deemed not suitable for enrollment by the researcher.

Where it's running

• Institute of Hematology & Blood Diseases Hospital, China
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Xin Chen, Doctor — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Xin Chen, Doctor
• Email: chenxin@ihcams.ac.cn
• Phone: 13920985705

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized T-cell therapy with a DC/AML fusion vaccine plus decitabine and venetoclax for AML

  This will try combining a personalized T-cell therapy and a DC/AML fusion vaccine with decitabine and venetoclax for people with newly diagnosed or relapsed AML to see if it is safe and can boost anti-leukemia immunity.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07374029

• Combining cytokine-induced memory-like natural killer cells with atezolizumab for relapsed or refractory AML

  This trial will test whether giving cytokine-induced memory-like natural killer cells together with atezolizumab is safe and might help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07011004

• Long-term safety follow-up of ARD103 CAR-T cells in relapsed/refractory AML and MDS

  This long-term follow-up study checks whether ARD103 CAR-T cell therapy remains safe for patients with relapsed or refractory AML or MDS after the initial treatment.

  Recruiting at 3 sites ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06906380

• Treatment with ARD103 CAR-T therapy for patients with relapsed or refractory AML or MDS

  This study is testing a new CAR-T therapy called ARD103 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 3 sites Phase 1/2 ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06680752

• MT-401-OTS treatment for relapsed AML or high‑risk MDS (safety focus)

  This trial will test whether escalating doses of an experimental off‑the‑shelf cell therapy called MT-401-OTS are safe and can reduce residual disease in adults aged 65 and older with relapsed or persistent AML or high‑risk MDS with low blast counts.

  Recruiting at 3 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06552416

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.